Common Polymorphisms in the MDM2 and TP53 Genes and the Relationship between TP53 Mutations and Patient Outcomes in Glioblastomas

被引:26
作者
Zawlik, Izabela [1 ]
Kita, Daisuke [1 ]
Vaccarella, Salvatore [1 ]
Mittelbronn, Michel [2 ]
Franceschi, Silvia [1 ]
Ohgaki, Hiroko [1 ]
机构
[1] Int Agcy Res Canc, Pathol Grp, F-69372 Lyon, France
[2] Univ Zurich Hosp, Dept Neuropathol, CH-8091 Zurich, Switzerland
关键词
glioblastoma; MDM2; amplification; SNP-309; p14(ARF) alteration; TP53; codon; 72; polymorphism; mutation; BREAST-CANCER CELLS; ESTROGEN-RECEPTOR-ALPHA; HUMAN-MALIGNANT GLIOMAS; LI-FRAUMENI-SYNDROME; LUNG-CANCER; CODON-72; POLYMORPHISM; PROTEIN EXPRESSION; COLORECTAL-CANCER; PROMOTER SNP309; POOR-PROGNOSIS;
D O I
10.1111/j.1750-3639.2008.00170.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
MDM2 SNP309 is associated with younger age of tumor onset in patients with Li-Fraumeni syndrome, and TP53 codon 72 polymorphism decreases its apoptotic potential. Glioblastomas frequently show genetic alterations in the TP53 pathway. In the present study, we assessed MDM2 SNP309 in 360 glioblastomas, and correlated these with patient age and survival, as well as other alterations in the TP53 pathway. Frequencies of the MDM2 SNP309 T/T, T/G and G/G genotypes in glioblastomas were 40%, 46% and 14%, respectively. Multivariate analysis showed that MDM2 SNP309 G/G allele was significantly associated with favorable outcome in female glioblastoma patients (hazard ratio 0.54; 95% CI = 0.32-0.92). There was a significant association between MDM2 SNP309 G alleles and TP53 codon 72 Pro/Pro in glioblastomas. Glioblastoma patients with TP53 codon 72 Pro/Pro genotype were significantly younger than Arg/Arg carriers (mean 50.2 vs. 56.1 years; P = 0.018). Multivariate analysis showed that those with TP53 codon 72 Arg/Pro allele had significantly shorter survival than those with Arg/Arg allele (hazard ratio 1.35; 95% CI = 1.07-1.71). Detailed analyses revealed that TP53 codon 72 Pro allele was significantly associated with shorter survival among patients with glioblastomas carrying a TP53 mutation, and among those treated with surgery plus radiotherapy.
引用
收藏
页码:188 / 194
页数:7
相关论文
共 59 条
  • [1] Afra D, 2002, LANCET, V359, P1011
  • [2] REGULATION OF MDM2 EXPRESSION BY P53 - ALTERNATIVE PROMOTERS PRODUCE TRANSCRIPTS WITH NONIDENTICAL TRANSLATION POTENTIAL
    BARAK, Y
    GOTTLIEB, E
    JUVENGERSHON, T
    OREN, M
    [J]. GENES & DEVELOPMENT, 1994, 8 (15) : 1739 - 1749
  • [3] Amplification and overexpression of MDM2 in primary (de novo) glioblastomas
    Biernat, W
    Kleihues, P
    Yonekawa, Y
    Ohgaki, H
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1997, 56 (02) : 180 - 185
  • [4] MDM2 is a central node in the p53 pathway: 12 years and counting
    Bond, GL
    Hu, WW
    Levine, AJ
    [J]. CURRENT CANCER DRUG TARGETS, 2005, 5 (01) : 3 - 8
  • [5] A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans
    Bond, GL
    Hu, WW
    Bond, EE
    Robins, H
    Lutzker, SG
    Arva, NC
    Bargonetti, J
    Bartel, F
    Taubert, H
    Wuerl, P
    Onel, K
    Yip, L
    Hwang, SJ
    Strong, LC
    Lozano, G
    Levine, AJ
    [J]. CELL, 2004, 119 (05) : 591 - 602
  • [6] Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome
    Bougeard, G.
    Baert-Desurmont, S.
    Tournier, I.
    Vasseur, S.
    Martin, C.
    Brugieres, L.
    Chompret, A.
    Bressac-de Paillerets, B.
    Stoppa-Lyonnet, D.
    Bonaiti-Pellie, C.
    Frebourg, T.
    [J]. JOURNAL OF MEDICAL GENETICS, 2006, 43 (06) : 531 - 533
  • [7] MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C
    Dharel, Narayan
    Kato, Naoya
    Muroyama, Ryosuke
    Moriyama, Masaru
    Shao, Run-Xuan
    Kawabe, Takao
    Omata, Masao
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (16) : 4867 - 4871
  • [8] The codon 72 polymorphic variants of p53 have markedly different apoptotic potential
    Dumont, P
    Leu, JIJ
    Della Pietra, AC
    George, DL
    Murphy, M
    [J]. NATURE GENETICS, 2003, 33 (03) : 357 - 365
  • [9] No association of MDM2 SNP309 with risk of glioblastoma and prognosis
    El Hallani, Soufiane
    Marie, Yannick
    Idbaih, Ahmed
    Rodero, Mathieu
    Boisselier, Blandine
    Laigle-Donadey, Florence
    Ducray, Francois
    Delattre, Jean-Yves
    Sanson, Marc
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2007, 85 (03) : 241 - 244
  • [10] Esteller M, 2000, CANCER RES, V60, P129